New drug cocktail targets tough colorectal cancer
NCT ID NCT06356597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a combination of three drugs—Tislelizumab, Fruquintinib, and Metronidazole—in 33 adults with advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if this mix can slow cancer growth and improve survival. Participants must have a specific type of cancer (MSS or MSI-L) and high levels of a certain bacteria in their stool.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (a drug that helps the immune system fight cancer) combined with Fruquintinib (a drug that blocks blood vessel growth to tumors) and Metronidazole (an antibiotic)
What this could lead to
If this works, it could offer a new treatment option for people with advanced colorectal cancer that hasn't responded to standard therapies.
What could go wrong
This is a small, early Phase 2 trial with only 33 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai First People's Hospital
Shanghai, China
-
Shanghai Ninth People's Hospital
Shanghai, China